ArticleClinical ophthalmology (Auckland, N.Z.)2019

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.

Mike Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.